QuidelOrtho Corporation logo

QuidelOrtho Corporation (QDEL)

Market Closed
10 Dec, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
28. 80
+1.36
+4.96%
$
1.87B Market Cap
- P/E Ratio
0% Div Yield
809,998 Volume
2.42 Eps
$ 27.44
Previous Close
Day Range
27.38 29.02
Year Range
19.5 49.45
Want to track QDEL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 62 days
QuidelOrtho Expands in Infectious Disease Testing With New FDA Nod

QuidelOrtho Expands in Infectious Disease Testing With New FDA Nod

QDEL announces the FDA's clearance for its VITROS syphilis assay, which boosts the company's infectious disease testing portfolio.

Zacks | 1 year ago
QuidelOrtho (QDEL) Up 3.8% Since Last Earnings Report: Can It Continue?

QuidelOrtho (QDEL) Up 3.8% Since Last Earnings Report: Can It Continue?

QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 year ago
QuidelOrtho (QDEL) Q2 Earnings Beat Estimates, U.S. Sales Down

QuidelOrtho (QDEL) Q2 Earnings Beat Estimates, U.S. Sales Down

QuidelOrtho's (QDEL) second-quarter results reflect growth in revenues. However, gross profit continues to decline.

Zacks | 1 year ago
QuidelOrtho Corporation (QDEL) Q2 2024 Earnings Call Transcript

QuidelOrtho Corporation (QDEL) Q2 2024 Earnings Call Transcript

QuidelOrtho Corporation (NASDAQ:QDEL ) Q2 2024 Earnings Conference Call July 31, 2024 5:00 PM ET Company Participants Juliet Cunningham - Vice President-Investor Relations Brian Blaser - President & Chief Executive Officer Joe Busky - Chief Financial Officer Conference Call Participants Jack Meehan - Nephron Research Casey Woodring - JPMorgan Patrick Donnelly - Citi Andrew Cooper - Raymond James Operator Welcome to the QuidelOrtho Second Quarter 2024 Financial Results Conference Call and Webcast. At this time, all participant lines are in a listen-only mode.

Seekingalpha | 1 year ago
QuidelOrtho (QDEL) Reports Q2 Loss, Tops Revenue Estimates

QuidelOrtho (QDEL) Reports Q2 Loss, Tops Revenue Estimates

QuidelOrtho (QDEL) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to earnings of $0.26 per share a year ago.

Zacks | 1 year ago
Here's Why You Should Retain QuidelOrtho (QDEL) Stock for Now

Here's Why You Should Retain QuidelOrtho (QDEL) Stock for Now

QuidelOrtho's (QDEL) strong product portfolio raises optimism about the stock.

Zacks | 1 year ago
The Schall Law Firm Encourages Investors Who Have Suffered Losses In QuidelOrtho Corporation To Make Contact

The Schall Law Firm Encourages Investors Who Have Suffered Losses In QuidelOrtho Corporation To Make Contact

LOS ANGELES, CA / ACCESSWIRE / June 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against QuidelOrtho Corporation ("QuidelOrtho" or "the Company") (NASDAQ:QDEL) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 18, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 11, 2024.

Accesswire | 1 year ago
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against QuidelOrtho Corporation - QDEL

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against QuidelOrtho Corporation - QDEL

NEW YORK, NY / ACCESSWIRE / June 9, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against QuidelOrtho Corporation ("QuidelOrtho" or the "Company") (NASDAQ:QDEL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

Accesswire | 1 year ago
The Schall Law Firm Urges Investors Who Have Experienced Losses In QuidelOrtho Corporation To Get In Touch

The Schall Law Firm Urges Investors Who Have Experienced Losses In QuidelOrtho Corporation To Get In Touch

LOS ANGELES, CA / ACCESSWIRE / June 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against QuidelOrtho Corporation ("QuidelOrtho" or "the Company") (NASDAQ:QDEL) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 18, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 11, 2024.

Accesswire | 1 year ago
The Schall Law Firm Encourages Investors Who Have Suffered Losses in QuidelOrtho Corporation to Make Contact

The Schall Law Firm Encourages Investors Who Have Suffered Losses in QuidelOrtho Corporation to Make Contact

LOS ANGELES, CA / ACCESSWIRE / June 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against QuidelOrtho Corporation ("QuidelOrtho" or "the Company") (NASDAQ:QDEL) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 18, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 11, 2024.

Accesswire | 1 year ago
Why Is QuidelOrtho (QDEL) Down 2.4% Since Last Earnings Report?

Why Is QuidelOrtho (QDEL) Down 2.4% Since Last Earnings Report?

QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 year ago
The Schall Law Firm Encourages Investors Who Have Suffered Losses In QuidelOrtho Corporation To Make Contact

The Schall Law Firm Encourages Investors Who Have Suffered Losses In QuidelOrtho Corporation To Make Contact

LOS ANGELES, CA / ACCESSWIRE / June 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against QuidelOrtho Corporation ("QuidelOrtho" or "the Company") (NASDAQ:QDEL) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 18, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 11, 2024.

Accesswire | 1 year ago
Loading...
Load More